"IKF wurde zum Ausbau und zur Förderung der klinischen Krebsforschung gegründet"

During the past decade, Institute for Clinical Cancer Research Krankenhaus Nordwest conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute for Clinical Cancer Research Krankenhaus Nordwest" #1 sponsor was "Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest" with 6 trials, followed by "Daiichi Sankyo, Inc." with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "BioNTech SE" with 1 trials sponsored and "Hoffmann-La Roche" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute for Clinical Cancer Research Krankenhaus Nordwest" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Trium Analysis Online GmbH" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "BioLineRx, Ltd." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Institute for Clinical Cancer Research Krankenhaus Nordwest" are "Gastroesophageal Junction Cancer" (2 trials), "Stomach Cancer" (2 trials), "Colorectal Cancer Stage II" (1 trials), "Colorectal Cancer Stage III" (1 trials) and "EGFR Exon 19 Deletion" (1 trials). Many other conditions were trialed in "Institute for Clinical Cancer Research Krankenhaus Nordwest" in a lesser frequency.

Most popular intervention types in "Institute for Clinical Cancer Research Krankenhaus Nordwest" are "Drug" (11 trials), "Biological" (4 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Ramucirumab" (4 trials), "Oxaliplatin" (3 trials), "Cetuximab" (2 trials), "Docetaxel" (2 trials) and "Encorafenib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Institute for Clinical Cancer Research Krankenhaus Nordwest" are 12 trials for "All" genders.

Currently, there are NaN active trials in "Institute for Clinical Cancer Research Krankenhaus Nordwest". undefined are not yet recruiting, 7 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Institute for Clinical Cancer Research Krankenhaus Nordwest, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Institute for Clinical Cancer Research Krankenhaus Nordwest, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".